Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals

Cancer Lett. 2018 Aug 28:430:215-223. doi: 10.1016/j.canlet.2018.03.045. Epub 2018 Apr 22.

Abstract

Clinical data indicates that T cells can be recruited to bladder cancer (BCa), yet the impact of T cells on BCa progression remains unclear. In the present study, we found that T cells were recruited more to BCa tissues than to the surrounding normal bladder tissues. Results from an in vitro co-culture system also found that BCa recruited more CD4+ T cells than did normal bladder cells. The recruiting of T cells to BCa tissues may increase the proliferation and invasion of BCa cells. Mechanistic studies revealed that infiltrating T cells stimulate BCa estrogen receptor beta (ERβ) signaling and consequently increase the expression of MET proto-oncogene, receptor tyrosine kinase (c-MET), through either direct binding to its promoter or via modulation of IL-1 expression. Interruption of ERβ/c-MET or ERβ/IL-1/c-MET signaling via ERβ-shRNA, IL-1 antagonist, or the c-MET inhibitor, SU11274, could partially reverse the T cell-enhanced BCa cell invasion and proliferation. Finally, the mouse BCa model with xenografted BCa 5637 cells with T (HH) cells confirmed the results of in vitro co-culture studies showing that infiltrating T cells could promote BCa metastasis via modulation of the ERβ/c-MET or ERβ/IL-1/c-MET signaling pathways. These findings may provide a new therapeutic approach to better combat BCa progression via targeting these newly identified signaling pathways.

Keywords: Bladder cancer; Estrogen receptor; Tumor microenvironment; c-MET.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / metabolism*
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Cystectomy
  • Disease Progression
  • Estrogen Receptor beta / antagonists & inhibitors
  • Estrogen Receptor beta / metabolism*
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Indoles / pharmacology
  • Interleukin-1 / antagonists & inhibitors
  • Interleukin-1 / metabolism*
  • Male
  • Mice
  • Mice, Nude
  • Neoplasm Invasiveness / pathology
  • Neoplasm Invasiveness / prevention & control
  • Piperazines / pharmacology
  • Promoter Regions, Genetic / genetics
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins c-met / antagonists & inhibitors
  • Proto-Oncogene Proteins c-met / genetics*
  • Proto-Oncogene Proteins c-met / metabolism
  • Pyrazoles / pharmacology
  • Pyrimidines / pharmacology
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Sulfonamides / pharmacology
  • Up-Regulation / drug effects
  • Urinary Bladder / cytology
  • Urinary Bladder / pathology
  • Urinary Bladder / surgery
  • Urinary Bladder Neoplasms / pathology*
  • Urinary Bladder Neoplasms / surgery
  • Xenograft Model Antitumor Assays

Substances

  • ((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)
  • 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol
  • ESR2 protein, human
  • Estrogen Receptor beta
  • Indoles
  • Interleukin-1
  • MAS1 protein, human
  • Piperazines
  • Proto-Oncogene Mas
  • Pyrazoles
  • Pyrimidines
  • Sulfonamides
  • MET protein, human
  • Proto-Oncogene Proteins c-met